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Gitelman syndrome (GS; OMIM 263800) is a rare auto-
somal recessive, inherited renal tubular disorder first
described by Gitelman et al in 1966 [1]. The prevalence
of GS is unknown, but one study published in 1988
estimated it to be 1.2 cases per million [2]. It is charac-
terized by hypokalemia, metabolic alkalosis, hypo-
magnesemia, and hypocalciuria. Herein, we report
three cases of GS, one sporadic and two siblings who
received treatment and had regular follow-up at our
pediatric clinic. We summarize these three cases and
discuss the previous literature on this disorder.
CASE PRESENTATIONS
Case 1
This patient was a 17-year-old girl born at term to unre-
lated parents. While being evaluated for an episode 
of pneumonia at another hospital, the patient was
incidentally found to have hypokalemia (2.6 mmol/L).
A review of medical history showed nothing remark-
able, including no history of laxative, diuretic abuse
or vomiting. Physical examination revealed a well-
developed girl without distress. There was no sign of
hypertension and cardiovascular examination showed
normal rate and rhythm without murmur, rubs, or
gallops. No abdominal tenderness, hepatosplenome-
galy, or peripheral edema was found. Neurologic
examination disclosed no sensory or motor deficit.
She did not have Chvostek and Trousseau sign.
Other laboratory values, analyzed at our hospital 
in March 1999 are shown in Tables 1–3. The abnor-
mal findings included hypokalemia (2.6 mmol/L),
metabolic alkalosis (pH 7.51 and bicarbonate 26.3
mmol/L) and hypomagnesemia (1.23 mmol/L). The
supine plasma renin was >20 ng/mL/hour (normal
range, 2.472.23 ng/mL/hour), and supine aldos-
terone was 63.19 pg/mL (normal range, 1–16 pg/mL),
but parathyroid hormone (iPTH) was 9 pg/mL (nor-
mal range, 10–65 pg/mL). The daily excretions of potas-
sium and calcium were 88.6 mmol/day and 16.8 mg/
day, respectively, and urine calcium/creatinine ratio
was 0.015.
She was treated with oral magnesium (450 mg/
day) and potassium (24 mmol/day) supplements for 
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persistent electrolyte imbalance. While on potas-
sium and magnesium supplements, her plasma potas-
sium and magnesium levels were still low (potassium
2.5 mmol/L and magnesium 1.39 mmol/L). The
patient’s 24-hour urine potassium excretion remained
at 88.66 mmol. After treatment, her plasma-free cal-
cium concentration was persistently low (ionized cal-
cium, 3.76 mg/dL) and post-treatment plasma level of
iPTH was 15.8 pg/mL (normal range, 10–65 pg/mL).
Case 2
This patient was an 18-year-old girl born at term with a
normal prenatal history. The patient presented in our
clinic with numbness over all extremities for 6 months.
Hypokalemia was found at that time (2.5 mmol/L).
She had no history of medication usage, including
diuretics and laxative. Physical examination in 1999
showed that she had a height of 152 cm (10th to 25th
percentile). She had no hypertension. Cardiovascular
examination showed a regular heart rate and rhythm
without murmur, rubs, or gallops. No abdominal ten-
derness, hepatosplenomegaly, or peripheral edema
was found. Neurologic examination revealed no 
sensory or motor deficit. There was no Chvostek or
Trousseau sign.
The initially abnormal laboratory values at our 
hospital in November 1999 showed hypokalemia 
(2.5 mmol/L), metabolic alkalosis (pH 7.46 and bicar-
bonate 32.7 mmol/L), and hypomagnesemia (1.39
mmol/L). Hormone examinations showed supine
plasma renin to be 20 ng/mL/hour (normal range,
2.472.23 ng/mL/hour), supine aldosterone to be
7.8 pg/mL (normal range, 1–16 pg/mL) and iPTH to be
17.7 pg/mL (normal range, 10–65 pg/mL). The daily
excretions of potassium and calcium were 91.7 mmol/
day and 32.8 mg/day, respectively. The urine calcium/
creatinine ratio was 0.05 (Tables 1–3).
She was treated with oral magnesium (450 mg/
day) and potassium (32 mmol/day) supplements.
While on potassium and magnesium supplements,
her plasma potassium and magnesium levels were
consistently low (potassium around 3.3 mmol/L and
magnesium around 1.39 mmol/L). After treatment,
her ionized plasma calcium was 4.64 mg/dL. The 
24-hour urine potassium and calcium excretion was
58.2 mmol and 21.7 mg, respectively. Further urine
examination showed the urine calcium/creatinine
ratio to be 0.28, potassium 58.2 mmol/day, and mag-
nesium 66.3 mg/day.
Case 3
This patient was a 13-year-old boy, a brother of case 
2, who had complained of numbness of the four
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Table 2. Serum electrolyte and hormone findings
Case 1 Case 2 Case 3
Electrolyte
Sodium (mmol/L) 139.0 138.0 138.0
Potassium (mmol/L) 2.6 2.5 2.7
Chloride (mmol/L) 97.0 96.0 97.0
Magnesium (mmol/L) 1.23 1.39 1.39
Calcium (mg/dL) 9.4 5.05 (i) 10.2
Phosphate (mg/dL) 4.2 4.6 4.9
Hormone
iPTH (pg/mL) 9 17.723 17.831
Renin (ng/mL/hr) 20 20 11.87
Aldosterone (ng/dL) 63.19 7.800 3.3
PTHparathyroid hormone; (i) ionized.
Table 1. Hematologic, biochemical, and arterial blood
gas findings
Case 1 Case 2 Case 3
Hematology
WBC (103/L) 6.3 8.6 9.4
Hb (g/dL) 12.6 13.5 13.9
MCV (m3) 69.0 83.5 78.3
PLT (103/L) 331.0 252.0 375.0
Biochemistry
Cr (mg/dL) 0.710 0.78 0.53
UA (mg/dL) — 6.3 5.80
Arterial blood gas
pH 7.401 7.461 7.496
PaCO2 (mmHg) 50.9 44.6 45.2
HCO3
– (mmol/L) 31.9 32.7 32.6
WBCwhite blood cell; Hbhemoglobin; MCVmean cor-
puscular volume; Crcreatinine; UAuric acid; PLTplatelet.
Table 3. Urinary findings
Case 1 Case 2 Case 3
pH 8.0 7.0 8.0
Ca/Cr (molar ratio) 0.015 0.05 0.03
24-hour Ca (mg/dL) 16.8 21.7 17.0
FEMg (%) 6.7 7.6 6.9
FEk (%) 20.75 25.78 22.76
Ccr (mL/min) 126.0 97.3 103.0
Ca/Crcalcium/creatinine ratio; FEMg fractional excretion
of magnesium; FEk fractional excretion of potassium; Ccr
creatinine clearance.
extremities for 1 week. Like his sister, he was found to
be a well-developed boy without distress. He also did
not have hypertension. His cardiovascular examina-
tion also showed a regular heart rate and rhythm with-
out murmur, rubs, or gallops. He was also found to
have no abdominal tenderness, hepatosplenomegaly,
or peripheral edema. Like his sister, he showed no signs
of sensory or motor deficit and had no Chvostek or
Trousseau sign.
The initial abnormal laboratory values at our hos-
pital in November 1999 were hypokalemia (2.7 mmol/
L), metabolic alkalosis (pH 7.46 and bicarbonate 32.6
mmol/L), and hypomagnesemia (1.39 mmol/L). Hor-
mone analysis showed supine plasma renin, 11.8 ng/
mL/hour (normal range, 2.472.23 ng/mL/hour),
supine aldosterone, 3.3 pg/mL (normal range, 1–16 pg/
mL) and iPTH, 17.8 pg/mL (normal range, 10–65 pg/
mL). The daily excretions of calcium and magnesium
were 17 and 77 mg/day, respectively, and urine 
calcium/creatinine ratio was 0.03 (Tables 1–3).
Like his sister, he was treated with oral magnesium
(450 mg/day) and potassium (32 mmol/day) supple-
ments. While on potassium and magnesium supple-
ments, his plasma potassium and magnesium levels
were consistently low (potassium around 2.5 mmol/L
and magnesium around 1.39 mmol/L). The serum-
free calcium concentration was persistently low 
(ionized calcium, 3.76 mg/dL). His 24-hour urine
potassium excretion was 34.1 mmol.
DISCUSSION
GS, a rare autosomal recessive inherited disorder first
described by Gitelman et al in 1966, is primarily a
renal tubular disorder characterized by hypokalemic
metabolic alkalosis, hypomagnesemia, and hypocal-
ciuria [1]. Epidemiologic studies have demonstrated
that there is no ethnic predilection for GS and both
sexes are equally affected. The prevalence of GS is
unknown, but one study published in 1988 estimated
it to be 1.2 cases per million in Sweden [2]. Although
many cases appear to be sporadic, the syndrome has
often been reported in siblings [1,3].
The marked similarity between the clinical fea-
tures of patients with GS and those of electrolyte
abnormalities induced by thiazide diuretics has led
investigators to study whether patients with GS
might have mutations that cause loss of function in
the thiazide-sensitive cotransporter (TSC), also called
the Na–Cl cotransporter (NCCT), which is located 
on the apical membrane in the distal convoluted tubule
[3–6]. Simon et al first demonstrated complete linkage
of GS to the NCCT gene (human gene mapping work-
shop approved symbol SLC12A3) on chromosome
16q13, and specified GS as an autosomal recessive
disorder with 99% penetrance [3]. This linkage to chro-
mosome 16q13 has been confirmed by others [7–9].
The defect in TSC leads to sodium chloride (NaCl)
wasting and hypovolemia, which stimulates the
renin–angiotensin–aldosterone system, and causes an
increase in apical Na reabsorption and stimulation
of the basolateral Na–K-ATPase. The elevated aldo-
sterone levels also stimulate H-ATPase pumps in the
cortical and medullary collecting ducts, leading to in-
creased apical H secretion. K and H excretion
increases as K enters from the basolateral membrane
via the Na–K-ATPase pumps, resulting in hypoka-
lemic metabolic alkalosis. Sodium reabsorption via
sodium channels is accompanied by potassium and
hydrogen ion excretion, resulting in hypokalemia
and further metabolic alkalosis. NaCl uptake through
the apical membrane decreases, whereas intracellular
Na continuously leaves the cells through the Na–
K-ATPase at the basolateral membrane. This extru-
sion of Na reduces intracellular Na concentration,
thereby hyperpolarizing distal convoluted tubular
cells and causing Ca2+ to enter the apical membrane
through Ca2+ channels [10]. Similarly, loss of TSC
function can inhibit reabsorption of Mg via an apical
Na/Mg exchanger. Since distal convoluted tubules
reabsorb approximately 5% of filtered magnesium
and the reabsorption is load-dependent [11], impair-
ment in magnesium reabsorption in this segment
would be expected to result in magnesium wasting
and hypomagnesemia, due to a lack of a detectable
magnesium transport system in the collecting duct.
Patients with GS are born at term with normal
amniotic fluid volume and do not have symptoms
throughout infancy and the preschool years. They are
often diagnosed in adolescence or early adulthood.
This disorder may be found during an occasional lab-
oratory investigation in asymptomatic patients or
patients with intermittent mild symptoms of muscle
weakness, fatigue, cramps, and carpopedal spasms.
However, severe symptoms such as tetany, rhabdo-
myolysis, and paralysis have been reported [12–14].
There is no prematurity, polyhydramnios, or polyuria.
Gitelman syndrome
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Sexual and mental maturation are normal, although
there has been a report of growth failure [15]. Chondro-
calcinosis, possibly due to hypomagnesemia, has also
been reported [16,17].
One study on the symptoms and health-related
quality of life (QOL) involved 50 adult GS patients
with confirmed mutation in NCCT [18]. Their most
common symptoms were salt craving (95%), muscu-
loskeletal symptoms such as cramps (84%), muscle
weakness and aches (70%), and constitutional symp-
toms such as fatigue (82%), dizziness (80%), nocturia
(80%), and polydipsia (65%). Health-related QOL was
significantly lower in GS patients than in controls, 
particularly with regard to role limitations caused by
physical health, emotion, energy levels, and general
health. Furthermore, the symptoms of GS did not 
correlate with the degree of laboratory abnormalities.
Almost all GS patients have hypokalemia, hypo-
magnesemia, metabolic alkalosis, and markedly
reduced urinary calcium excretion. The molar ratio of
urinary calcium to urinary creatinine is 0.1 [19,20].
Chloride clearance increases after furosemide but 
not after thiazides. Normal urinary excretion of
prostaglandin E2 (PGE2), and normal serum PTH, 
25-hydroxyvitamin D3, and 1,25-dihydroxyvitamin D3
levels have been reported.
GS should be differentiated from Bartter syn-
drome [14]. Clinically, the two have been distin-
guished based on serum magnesium and urinary
calcium findings, with GS denoting the subset with
hypomagnesemia and hypocalciuria. An additional
subset, patients with Bartter syndrome who present
neonatally and typically have nephrocalcinosis, has
been recognized. Patients with Bartter syndrome typ-
ically present before the age of 6 years with severe
symptoms such as dehydration and growth retarda-
tion. In contrast, patients with GS typically present in
early adulthood and with predominantly neuromus-
cular symptoms. In addition, genetic analysis may
further differentiate the two syndromes with com-
plete linkage of GS to the locus encoding NCCT on
chromosome 16q13.
The mainstay treatment for GS is oral potassium
chloride supplementation. However, treating hypo-
kalemia is generally very difficult. Large amounts of
oral potassium (up to 10 mmol/kg/day in children
or 500 mmol/day in adults) may be required [14].
Large amounts of exogenous potassium may exacer-
bate the renal potassium loss by further increasing
aldosterone synthesis [21,22]. The addition of potas-
sium-sparing diuretics may lessen the hypokalemia
and its associated symptoms. Concurrent oral mag-
nesium supplementation is also used in the treat-
ment of GS. Magnesium must be administered 4 or 5
times daily and the doses required often induce diar-
rhea. Magnesium chloride also helps replace urinary
chloride losses, though many other magnesium salts
have been used. Magnesium therapy not only corrects
the hypomagnesemia and other mineral disorders,
but also improves hypokalemia [23,24]. Long-term
prognosis is dependent on growth maintenance and
preservation of renal function. Life expectancy is
excellent.
Our three patients included one sporadic case 
and two siblings. The sporadic case was incident-
ally found to have hypokalemia without significant 
predisposing factors. The two siblings presented
with symptoms of extremity numbness and had
hypokalemia and hypomagnesemia. According to the
previous report in Taiwanese patients, gender may
play an important role in explaining the different clin-
ical presentations in familiar GS [25]. However, our
case 2 and 3, sister and brother in a family, had similar
clinical presentations and laboratory data. Whether
the difference is due to the age of the patients studied
is unknown. In addition, lack of genetic study may
limit our further discussion to differentiate the differ-
ence between two studies.
In conclusion, these three cases reminded us that
unexplained hypokalemia may be caused by renal
tubular diseases, such as GS. Detailed electrolyte analy-
sis and hormone evaluations are mandatory for differ-
ential diagnosis. GS is characterized by hypokalemia,
metabolic alkalosis, hypomagnesemia, and hypocalci-
uria. Though genetic analysis will further confirm the
diagnosis, their clinical presentations were compatible
with GS. These three cases remind us that doctors
should be alert to unexplained hypokalemia, which is
usually the initial presentation of GS.
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